Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials

Meta-analysis (5 RCTs; n=11 816) found low-dose colchicine reduced risk of major adverse cardiovascular events (RR 0.75, 95% CI 0.61–0.92), MI (0.78; 0.64–0.94;), stroke (0.54; 0.34–0.86;), and coronary revascularization (0.77; 0.66–0.90).

European Heart Journal